Sign in
Enrolling by invitationNo phase

Follow-up of a new knee replacement implant in people with knee arthritis

Follows how safe and effective a knee replacement implant is after surgery.

Key facts

Who runs it
MicroPort Orthopedics Inc.
Where
Fremont, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
Status
Enrolling by invitation
People taking part
150 people, planned
Started
27 Jan 2022
Expected to end
Jan 2035
Type of study
Observational
Treatments tested
  • EVOLUTION® NitrX™
Record updated
20 March 2024

Who can take part

The trial is looking for adults who have had, or will have, a first total knee replacement (TKA) with the EVOLUTION® NitrX™ components. Doctors will follow them for 10 years after surgery.

Age
21 years and older
Sex
All sexes
Disease stage
Knee joint disease that needs a first knee replacement. This includes osteoarthritis, arthritis after an injury, avascular necrosis (bone death from poor blood flow), rheumatoid arthritis, or correcting a joint deformity.
Earlier treatment
People must have had, or plan to have, a first TKA with the EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert. People who already have the implant must join within 14 months of surgery.
Main reasons for not taking part
  • Under 21 years of age, or bones still growing, at the time of surgery
  • An infection at the time of surgery, in the knee or elsewhere in the body
  • Fast joint destruction or bone loss seen on X-ray, weak bone, or poor skin around the joint
  • Weak nerves or muscles, for example past paralysis
  • Drug or alcohol abuse, being in prison, or a condition that stops you following the study
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Has previously undergone or currently has determined to undergo a primary TKA with the specified combination of components: EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert
  • Has previously undergone or currently has determined to undergo a primary TKA for any of the following:; non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis; inflammatory degenerative joint disease including rheumatoid arthritis; correction of functional deformity
  • Willing to voluntarily sign the informed consent form
  • Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit
  • Previously implanted subjects must be enrolled within 14 months of their primary TKA implantation; Prospective enrollment of a previously unimplanted contralateral knee is permitted in this study provided:
  • the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) are used,
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  • the subject agrees to a second Informed Consent document and data collection specific to the second TKA; Bilateral subjects can have both TKAs enrolled in the study provided:
  • the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) were implanted in both,
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  • the subject agrees to a second Informed Consent document and data collection specific to the second TKA; Bilateral implantation can occur at different time periods for the same subject

Who cannot take part

  • Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
  • Has or had an overt infection at the time of implantation
  • Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation
  • Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation
  • Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  • Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol
  • Skeletally immature (less than 21 years of age) at time of implantation
  • Currently enrolled in another clinical investigation which could affect the endpoints of this protocol
  • Has documented substance abuse issues
  • Currently incarcerated or has impending incarceration

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

Where in United States

Also in 1 other country, 1 site

  • Sah Orthopaedic AssociatesFremont, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the European Union (EU). MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur. These components are used along with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert components that is marketed in the European Union (EU). This type of data collection is required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available.

The group in the trial

  • Newly or previously implanted patients

    Multicenter, non-interventional prospective follow-up of newly or previously implanted subjects. Previously implanted subjects must be enrolled within 14 months of the study index surgery. Single study group with either newly or previously implanted patients with all EVOLUTION® NitrX™ components: Non-Porous Keeled Tibia, CS/CR Non-Porous Femur component, and EVOLUTION® MP CS tibial insert

    Treatment: EVOLUTION® NitrX™

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
Plain-language title
Follow-up of a new knee replacement implant in people with knee arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT04816773, who can take part
Record updated
20 March 2024